QIAGEN
Supplies sample technologies, molecular diagnostics, PCR and genomics tools for research and clinical testing.
Something off on this page? Send us feedback.
Profile
Sells consumables, instruments and software that move biological samples from preparation through molecular analysis. Its workflow serves life-science research and clinical diagnostics, with sample technologies, diagnostic solutions, PCR and genomics as core pillars.
Connects sample technologies, diagnostic solutions, PCR and nucleic-acid amplification, genomics and NGS, plus related software and automation. QuantiFERON, QIAstat-Dx and QIAcuity are current pillars within workflows that take biological samples from preparation through molecular analysis. Built from a nucleic-acid preparation base, the portfolio now extends into assays, instruments and data interpretation.
Serves life-science customers in academia, pharmaceutical R&D, industrial work and forensics, alongside clinical healthcare customers. Operations are international across more than 35 locations. The business depends on combining sample preparation, assays, bioinformatics and automation within one Sample to Insight workflow.
Company facts
Key statistics
Year to date −9.4% · Average volume (30d) 2.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Stifel Nicolaus | Target | $36 | $40 | |
| Aug 7, 2026 | Barclays | Reiterate | Equal Weight | $38 | $40 |
| Aug 6, 2026 | Jefferies | Reiterate | Buy | $59 | $48 |
| Jul 14, 2026 | Berenberg Bank | Target | $45.50 | ||
| Jun 25, 2026 | Kepler Capital | Target | $38.60 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.60 | $0.62 | +3.7% | $527.5M | $535.0M | +1.4% | −0.52% |
| May 6, 2026Q1 FY26 | $0.54 | $0.54 | −0.4% | $496.1M | $492.3M | −0.8% | −2.70% |
| Feb 4, 2026Q4 FY25 | $0.61 | $0.62 | +1.6% | $528.4M | $540.4M | +2.3% | −0.93% |
| Nov 4, 2025Q3 FY25 | $0.61 | $0.64 | +4.9% | $525.9M | $532.6M | +1.3% | −0.25% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $483.5M | $533.5M | $532.6M | $540.4M | $492.3M | $535.0M | |
| Gross profit | $308.7M | $334.3M | $331.3M | $317.3M | $309.6M | $340.4M | |
| Operating income | $115.3M | $121.9M | $129.2M | $153.9M | $116.6M | $132.4M | |
| Net income | $90.8M | $96.3M | $130.0M | $107.8M | $68.0M | $103.4M | |
| Diluted EPS | $0.41 | $0.44 | $0.60 | $0.52 | $0.33 | $0.50 | |
| Gross margin | 63.8% | 62.7% | 62.2% | 58.7% | 62.9% | 63.6% | |
| Operating margin | 23.9% | 22.8% | 24.3% | 28.5% | 23.7% | 24.7% |
Fiscal years (4-quarter sums)FY21 $2.25B · FY22 $2.14B · FY23 $1.97B · FY24 $1.98B · FY25 $2.09B
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $793.5M · Total debt $1.64B · Total assets $5.89B · Shareholders' equity $3.36B
Dividends
Last cut to $0.35 from $2.29 in Jul 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 7, 2026 | Jul 7 | Jul 14 | $0.35 | cut from $2.29 |
| Jan 8, 2026 | Jan 8 | $2.29 | raised from $0.25 | |
| Jul 2, 2025 | Jul 2 | Jul 10 | $0.25 | cut from $1.296 split-adjusted |
| Jan 29, 2025 | Jan 29 | Jan 29 | $1.26 | |
| Jan 30, 2024 | Jan 31 | Jan 31 | $1.28 | special dividend |
Ownership
Shares outstanding 206.25M · Float 204.78M · 99.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Wellington Management Group LLP | 12.41M | 6.02% | 13F | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 11.35M | 5.51% | 13F | Aug 14, 2026 |
| Principal Financial Group Inc | 6.65M | 3.22% | 13F | Aug 4, 2026 |
| Vanguard Capital Management LLC | 6.21M | 3.01% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 5.91M | 2.86% | 13F | Aug 7, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Thermo Fisher Scientific
Overlaps in sample prep, PCR, and end-to-end genomics
- Danaher
Overlaps in sample-to-answer PCR and clinical molecular testing
- Bio-Rad Laboratories
Direct digital-PCR rival with a broad ddPCR assay portfolio
- Illumina
NGS platforms, library prep, and analysis overlap in genomics
- Agilent Technologies
Overlaps in genomics tools, qPCR, and clinical-lab workflows
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Illumina | $215.70 | +0.02% | $32.62B | 40.2 | 37.6 | 7.3 | +9.4% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Median | 38.4 | 24.3 | 5.9 | +8.1% |